GLENMARK PHARMACEUTICALS LTD. - Clarifies on News Item

	< Back
05 Jan 2016
The Exchange had sought clarification from the company with respect to news article appearing in DNA on January 04, 2016 titled "Roche, Glenmark settle dispute over cancer drug".<BR><BR>The company replied stating "Glenmark confirms that it has reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride. As part of the agreement, the companies have ceased all relevant patent litigation on this product. The settlement is a part of normal course of our business and it will have no material impact on the company."
View all announcements for GLENMARK PHARMACEUTICALS LTD.	Source: BSE India

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us